浏览全部资源
扫码关注微信
非瓣膜性房颤老年患者达比加群的群体药动学研究
Study on population pharmacokinetics of dabigatran in elderly patients with non-valvular atrial fibrillation
- 中国药房 2023年34卷第14期 页码：1734-1738
- 作者机构：
苏州大学附属第二医院药学部，江苏 苏州 215004
- 作者简介：
药师，硕士。研究方向：临床药学和个体化给药。电话：0512-67783646。E-mail：18260091898@163.com
主管药师，硕士。研究方向：临床药学和个体化给药。电话：0512-67783646。E-mail：wwdz_@126.com
- 基金信息：江苏省研究型医院学会-精益化用药-石药专项科研基金(JY202009);江苏省药学会-奥赛康医院药学基金(A201814);江苏省药学会-天晴医院药学基金(Q2019055)
DOI：10.6039/j.issn.1001-0408.2023.14.14
中图分类号： R972;R969.1纸质出版日期：2023-07-30，
收稿日期：2022-11-01，
修回日期：2023-06-26，
扫 描 看 全 文
赵琴虹,屈昱晨,杨叶舟等.非瓣膜性房颤老年患者达比加群的群体药动学研究 Δ[J].中国药房,2023,34(14):1734-1738.
ZHAO Qinhong,QU Yuchen,YANG Yezhou,et al.Study on population pharmacokinetics of dabigatran in elderly patients with non-valvular atrial fibrillation[J].ZHONGGUO YAOFANG,2023,34(14):1734-1738.
赵琴虹,屈昱晨,杨叶舟等.非瓣膜性房颤老年患者达比加群的群体药动学研究 Δ[J].中国药房,2023,34(14):1734-1738. DOI： 10.6039/j.issn.1001-0408.2023.14.14.
ZHAO Qinhong,QU Yuchen,YANG Yezhou,et al.Study on population pharmacokinetics of dabigatran in elderly patients with non-valvular atrial fibrillation[J].ZHONGGUO YAOFANG,2023,34(14):1734-1738. DOI： 10.6039/j.issn.1001-0408.2023.14.14.
摘要
目的
2
分析影响非瓣膜性房颤老年患者达比加群暴露的因素。
方法
2
收集2019年1月－2020年6月于我院就诊并确诊为非瓣膜性房颤的75例患者资料，每位患者采集1～2个稳态血药浓度样本。采用NONMEM 7.2.0软件建立患者的达比加群群体药动学模型，考察不同协变量对达比加群表观清除率的影响，并通过拟合优度及Bootstrap法对最终模型进行验证；采用NONMEM 7.2.0软件分析不同疾病状态下普通老年患者及高龄老年患者服用达比加群酯后的药物暴露。
结果
2
共采集到122个达比加群的血药浓度样本。高龄、肌酐清除率及慢性心力衰竭史是影响老年患者达比加群清除率的显著协变量。高龄老年患者暴露相比于普通老年患者增加约50%，合并慢性心力衰竭患者相比于未合并慢性心力衰竭患者暴露增加近30%，中、重度肾功能损伤患者相比于轻度肾功能损伤患者暴露分别增加约30%、80%。
结论
2
高龄、肾功能损伤、慢性心力衰竭史是引起达比加群体内暴露增加的影响因素。
Abstract
OBJECTIVE
2
To analyze influential factors for dabigatran exposure in elderly patients with non-valvular atrial fibrillation.
METHODS
2
The clinical information of 75 elderly patients diagnosed with non-valvular atrial fibrillation was collected from our hospital in Jan. 2019-Jun. 2020. One or two steady-state blood drug concentration samples were collected from each patient. NONMEM 7.2.0 software was used to establish a population pharmacokinetics model of dabigatran； the effects of different covariates on the apparent clearance of dabigatran were investigated， and the final model was verified by goodness of fit and Bootstrap method； NONMEM 7.2.0 software was used to analyze the drug exposure of ordinary elderly patients and elderly patients after taking dabigatran ester in different disease states.
RESULTS
2
Totally 122 blood concentration samples of dabigatran were collected. Advanced age， creatinine clearance and history of chronic heart failure were screened out as three significant covariates that influenced the clearance of dabigatran in elderly patients. The exposure of population with advanced age increased by about 50% compared with the general elderly， the exposure of population with history of chronic heart failure increased by nearly 30% compared with population without， and the exposure of population with moderate and severe renal injury increased by about 30% and 80% compared with mild.
CONCLUSIONS
2
Advanced age， renal injury and history of chronic heart failure are influential factors for elevated systemic exposure of dabigatran.
关键词
达比加群非瓣膜性房颤群体药动学老年患者
Keywords
non-valvular atrial fibrillationpopulation pharmacokineticselderly patient
references
World Health Organization. Ageing and health[EB/OL].[2023-06-14]. https：//www.who.int/en/news-room/fact-sheets/detail/ageing-and-healthhttps://www.who.int/en/news-room/fact-sheets/detail/ageing-and-health.
DI NISIO M，MIDDELDORP S，BÜLLER H R. Direct thrombin inhibitors[J]. N Engl J Med，2005，353（10）：1028-1040.
EIKELBOOM J W，WALLENTIN L，CONNOLLY S J，et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation：an analysis of the randomized evaluation of long-term anticoagulant therapy（RE-LY）trial[J]. Circulation，2011，123（21）：2363-2372.
REILLY P A，LEHR T，HAERTTER S，et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major blee-ding in atrial fibrillation patients：the RE-LY Trial（rando-mized evaluation of long-term anticoagulation therapy）[J]. J Am Coll Cardiol，2014，63（4）：321-328.
陈敏，阳丽梅，罗冬梅，等.HPLC-MS/MS法测定人血浆中达比加群的浓度[J].福建医药杂志，2018，40（6）：118-123.
BARRA S，PROVIDÊNCIA R，FAUSTINO C，et al. Performance of the cockcroft-gault，MDRD and CKD-EPI formulae in non-valvular atrial fibrillation：which one should be used for risk stratification?[J]. J Atr Fibrillation，2013，6（3）：896.
LIESENFELD K H，LEHR T，DANSIRIKUL C，et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial[J]. J Thromb Haemost，2011，9（11）：2168-2175.
WÄHLBY U，JONSSON E N，KARLSSON M O. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis[J]. AAPS PharmSci，2002，4（4）：E27.
Compendium Suisse des Médicaments. Infromation professionnelle du compendium suisse des médicaments：pradaxa[EB/OL].[2023-06-14]. https：//compendium.ch/product/1366386-pradaxa-caps-110-mg/mprohttps://compendium.ch/product/1366386-pradaxa-caps-110-mg/mpro.
GOMMANS E，GROULS R J E，KERKHOF D，et al. Dabigatran trough concentrations in very elderly patients[J]. Eur J Hosp Pharm，2021，28（4）：231-233.
BOLEK T，SAMOŠ M，ŠKORŇOVÁ I，et al. Dabigatran levels in elderly patients with atrial fibrillation：first post-marketing experiences[J]. Drugs Aging，2018，35（6）：539-544.
ANTONIJEVIC N M，ZIVKOVIC I D，JOVANOVIC L M，et al. Dabigatran-metabolism，pharmacologic properties and drug interactions[J]. Curr Drug Metab，2017，18（7）：622-635.
MIKI Y，SUZUKI T，TAZAWA C，et al. Steroid and xenobiotic receptor（SXR），cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues[J]. Mol Cell Endocrinol，2005，231（1/2）：75-85.
GOUIN-THIBAULT I，DELAVENNE X，BLANCHARD A，et al. Interindividual variability in dabigatran and riva-roxaban exposure：contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin[J]. J Thromb Haemost，2017，15（2）：273-283.
DIMATTEO C，D’ANDREA G，VECCHIONE G，et al. Pharmacogenetics of dabigatran etexilate interindividual variability[J]. Thromb Res，2016，144：1-5.
PARÉ G，ERIKSSON N，LEHR T，et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding[J]. Circulation，2013，127（13）：1404-1412.
0
浏览量
13
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：重庆市渝中区大坪正街129号四环大厦8层 400042
- 技术支持由北京北大方正电子有限公司提供 渝ICP备15012710号
公网安备50010302001817 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies